Back to search

Article

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

2023-12-08

Abstract excerpt

<h4>Background</h4> The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, a decentralized HRD test based on low...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
564d95cf-4e98-55ff-8a3e-022520b95355
DOI
10.1101/2023.12.07.23299362
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancerDOI 10.1101/2023.12.07.23299362
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trialSemantic proximity
Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinomaSemantic proximity
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.Semantic proximity
Developing a whole exome sequencing-based homologous recombination deficiency test of epithelial ovarian cancerSemantic proximity
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian CarcinomaSemantic proximity
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World CohortSemantic proximity
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian CancerSemantic proximity
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.Semantic proximity
HRD-One: CLINICAL VALIDATION AND PERFORMANCE ASSESSMENT. Comparison between Myriad’s myChoice®, SOPHiA GENETICS® SOPHiA Homologous Recombination Solution and AmoyDx® HRD Focus PanelSemantic proximity
Combination of<i>BRCA</i>deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancerSemantic proximity
Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancerSemantic proximity
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.Semantic proximity
Select a neighboring publication to make it the new centre.